NICOTROL (nicotine) by Pfizer is pharmacologic action nicotine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. First approved in 1997.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
NICOTROL is a nicotine inhalant approved in 1997 for smoking cessation. It delivers nicotine via oral inhalation, binding to nicotinic-cholinergic receptors in the brain to produce stimulant and reward effects that reduce cravings. The product addresses nicotine dependence by providing a pharmaceutical alternative to tobacco smoking.
As LOE approaches, the NICOTROL brand team is likely consolidating to defend market share against generic and OTC competitors; career growth will focus on retention strategy rather than expansion.
Pharmacologic Action Nicotine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Two types of central nervous system effects are believed to be the basis…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes
Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
Nicotine Influence on the Retina Following the Use of Electronic Cigarette
Comparative Effectiveness of Cystine Versus Nicotine Replacement Therapy
Worked on NICOTROL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on NICOTROL offers limited career growth due to LOE approaching and minimal linked job openings (0 reported). This is a defensive, mature brand role suitable for professionals focused on managing decline, generic competition strategy, and cost-of-goods optimization rather than launching or scaling a growth product.